11/12
06:43 am
lsta
Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/9
12:53 am
lsta
Lisata (LSTA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Lisata (LSTA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/7
12:20 am
lsta
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... [Yahoo! Finance]
Medium
Report
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... [Yahoo! Finance]
11/6
04:05 pm
lsta
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/6
08:00 am
lsta
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
Low
Report
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
11/4
04:00 pm
lsta
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
High
Report
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
10/30
08:00 am
lsta
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
Low
Report
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
10/14
07:58 am
lsta
Lisata Therapeutics (NASDAQ:LSTA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Lisata Therapeutics (NASDAQ:LSTA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/13
08:10 am
lsta
Lisata Therapeutics to Present at LD Micro Main Event XIX [Yahoo! Finance]
Low
Report
Lisata Therapeutics to Present at LD Micro Main Event XIX [Yahoo! Finance]
10/8
08:56 am
lsta
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement [Yahoo! Finance]
Low
Report
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement [Yahoo! Finance]
10/8
08:30 am
lsta
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Medium
Report
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
10/7
09:22 am
lsta
GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025 [Yahoo! Finance]
Low
Report
GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025 [Yahoo! Finance]
10/3
03:40 pm
lsta
Lisata Therapeutics (NASDAQ:LSTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lisata Therapeutics (NASDAQ:LSTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/29
08:16 am
lsta
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial [Yahoo! Finance]
Medium
Report
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial [Yahoo! Finance]
9/29
08:00 am
lsta
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Low
Report
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial